Research suggests that a new type of antipsychotic, xanomeline and trospium chloride (Cobenfy), is associated with significant improvements in cognitive symptoms among people with schizophrenia.

The company successfully launched Cobenfy, a novel treatment for schizophrenia, marking a significant milestone in their neuroscience portfolio. Operational excellence and financial discipline led ...

Corewell Health is the first medical system in the state to announce that it is limiting gender-affirming care for minor patients. It will no longer allow minors seeking such treatment to start ...

But the company is counting on big things from Cobenfy, its new schizophrenia drug, is the first new treatment for the disease in 30 years. This has blockbuster potential, but it’s still too ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Then I will speak to the promise we see with Cobenfy and the steady cadence of clinical data catalysts that will begin this year, further defining our future growth potential. I will end with an ...

Shares of Bristol Myers fell to $58.08. The stock is up around 25% over the past year, driven in part by investor enthusiasm for its new schizophrenia drug Cobenfy, which was approved by the FDA last ...

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...

Bristol Myers added that it expected the U.S. approval last year of its Cobenfy treatment for patients with schizophrenia would be a driver of growth. The company also said it was expanding a ...

The company celebrated significant milestones in its product pipeline, notably the FDA approval of Cobenfy and the promising regulatory path of Opdivo-related treatments. These achievements ...